institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 2 days ago • loading... • Updated 2 days ago

Biogen Declares Phase 2 Lupus Success for Anti-BDCA2 Antibody

Summary by endpoints.news

Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline. The drug litifilimab improved patients’ skin lesions after 24 weeks, with 14.7% reaching ...

10 Articles

10 Articles

The Toronto Star

+8 Reposted by 8 other sources

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab

2 days ago·Toronto, Canada

Read Full Article

Biogen declares Phase 2 lupus success for anti-BDCA2 antibody

Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline. The drug litifilimab improved patients’ skin lesions after 24 weeks, with 14.7% reaching ...

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources10

Leaning Left6Leaning Right1Center1Last Updated1 day agoBias Distribution

75% Left

Bias Distribution

75% of the sources lean Left

75% Left

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada 2 days ago on Saturday, March 28, 2026.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics